Figure 3
Figure 3. The approach to therapy in patients with mixed-phenotype acute leukemia (MPAL). Targeted therapy based on a patient’s specific genetic profile should be considered in refractory/relapse patients (eg, MLL rearrangements, FLT3-ITD, IDH1, IDH2).

The approach to therapy in patients with mixed-phenotype acute leukemia (MPAL). Targeted therapy based on a patient’s specific genetic profile should be considered in refractory/relapse patients (eg, MLL rearrangements, FLT3-ITD, IDH1, IDH2).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal